Descriptive statistics and summary of psychological outcomes of TP53 carriers requiring further investigations vs with those not requiring further investigations
| Scale | Scale range/threshold | Study enrolment | 12 weeks after results* | +26 weeks after results* | 52 weeks after results* | ||||
| No investigations (n=28) | Further investigations (n=16) | No investigations (n=20) | Further investigations (n=9) | No investigations (n=18) | Further investigations (n=13) | No investigations (n=18) | Further investigations (n=10) | ||
| HADS Anxiety, mean (SD); n above threshold | 0–21 | 6.0 (4.4) | 6.6 (3.1) | 5.2 (4.5) | 7.2 (3.5) | 5.6 (3.4) | 6.3 (5.0) | 5.6 (5.0) | 5.8 (4.8) |
| 0–7 | 18 | 11 | 14 | 5 | 13 | 9 | 13 | 6 | |
| 8–10 | 5 | 4 | 3 | 2 | 4 | 3 | 2 | 3 | |
| >10 | 5 | 1 | 3 | 2 | 1 | 1 | 3 | 1 | |
| HADS Depression mean (SD); n above threshold | 0–21 | 1.8 (1.9) | 3.1 (3.1) | 1.9 (3.1) | 3.0 (3.8) | 2.1 (2.4) | 3.2 (3.2) | 2.7 (3.0) | 3.6 (5.1) |
| 0–7 | 28 | 14 | 18 | 8 | 16 | 11 | 16 | 9 | |
| 8–10 | 0 | 0 | 1 | 0 | 2 | 2 | 2 | 0 | |
| >10 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | |
| CWS-R, mean (SD) | 8–32 | 13.7 (2.1) | 15.6 (5.1) | 13.2 (2.4) | 14.6 (7.1) | 14.4 (3.6) | 15.1 (5.3) | 14.0 (3.4) | 15.4 (5.7) |
| IES: cancer intrusion | 0–35 | – | – | 8.6 (8.4) | 7.4 (11.0) | 10.3 (9.7) | 11.9 (10.8) | 8.2 (6.6) | 10.9 (10.6) |
| 0–8 | 11 | 7 | 9 | 6 | 9 | 5 | |||
| >8 | 8 | 2 | 9 | 7 | 8 | 5 | |||
| IES: cancer avoidance | 0–40 | – | – | 9.1 (7.9) | 11.6 (11.4) | 11.0 (11.6) | 16.6 (11.6) | 8.2 (7.6) | 13.3 (11.6) |
| 0–8 | 8 | 4 | 9 | 3 | 9 | 3 | |||
| >8 | 11 | 5 | 9 | 10 | 8 | 7 | |||
*n=number of questionnaires returned at each time-point. Participants receiving a cancer diagnosis did not complete questionnaires beyond the time of diagnosis.
CWS-R, Cancer Worry Scale Revised; HADS, Hospital Anxiety and Depression Scale; IES, Impact of Events Scale.